3 Results for "

P9915

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "P9915" in MCE Product Catalog:

11
11 Cited Publications
Cat. No.: HY-P9915
CAS No.: 945721-28-8
Synonyms: Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414

Target:  

CD38 ADC Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-P9915A
CAS No.: 945721-28-8
Synonyms: Anti-Human CD38, Human Antibody (PBS)

Target:  

ADC Antibodies CD38

Research Areas:  

Cancer

Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
Cat. No.: HY-160696
CAS No.: 2641306-62-7
Target:  

CD73

Research Areas:  

Cancer

ORIC-533 is an orally active, highly selective, AMP-competitive CD73 inhibitor that potently blocks adenosine production with sub-nanomolar affinity (Ka=0.03 nM). In multiple myeloma, ORIC-533 restores and enhances the cytotoxicity of the immune system against tumor cells through multiple immunological mechanisms, including reversing the immunosuppressive microenvironment, inducing immunogenic cell death, and activating dendritic cells, T cells and NK cells, with no direct toxicity to normal cells. The combination of ORIC-533 with Daratumumab (HY-P9915) synergistically enhances anti-tumor efficacy, significantly increases intratumoral CD8 + T cell infiltration and inhibits tumor growth in vivo .
loading...
    loading...